Tactile Systems Technology
Tactile Systems Technology's revenue rose 12.5% to $330 million in fiscal 2025. Its operating margin was 8.9%, up from 7.6% a year earlier. Free cash flow was $40 million, up 5.7%. It paid out $27 million in dividends and buybacks, 66% of free cash flow. The diluted share count fell 3.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Tactile Systems Technology does
Tactile Systems Technology, which does business as Tactile Medical, makes medical devices that people use at home to treat long-term conditions. Its focus is vascular disease, mainly lymphedema (chronic swelling when the lymph system can't drain fluid) and chronic venous insufficiency, cancer-related lymphedema, and airway clearance for people with chronic lung conditions.
It sells in two ways. For its lymphedema products it deals directly with patients and clinicians: it gets referrals, handles insurance claims, delivers the device and trains the patient. For its AffloVest airway clearance product it sells to accredited durable medical equipment providers, who handle the payer paperwork and patient support.
In 2025 it had revenue of $329.5 million and net income of $19.1 million. Revenue rose 12% from 2024. It says most of its revenue comes from lymphedema products, and that Medicare and other insurers' coverage rules matter greatly to its sales.
Its biggest risks, as it describes them
- Changes in Medicare coverage rules, or insurers' reimbursement, could hurt sales of its products.
- Its revenue comes mainly from lymphedema products, so it is highly dependent on them.
- It must expand and manage its direct sales teams and its relationships with distributors.
- It buys some parts from single-source suppliers, and losing one could disrupt production.
- Doctors and insurers may demand more clinical studies before prescribing or covering its products.
Income statement
From fiscal 2016 to 2025, earnings per share grew 20.8% a year and net income 23.3% a year, as new shares raised the share count by 116% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 28 | 22 | 61 | 94 | 83 |
| Debt incl. finance leases | 30 | 24 | 29 | 26 | 0 |
| Net debt (negative means net cash) | 2 | 2 | −32 | −68 | −83 |
| Net debt to EBITDA | 0.9x | — | −1.3x | −2.4x | −2.3x |
| Debt to equity | 0.2x | 0.2x | 0.1x | 0.1x | 0.0x |
| Interest coverage | −13.6x | −4.6x | 4.3x | 10.6x | 28.2x |
| Current ratio | 3.3x | 1.9x | 3.5x | 4.4x | 4.0x |
| Quick ratio | 2.7x | 1.5x | 3.0x | 3.9x | 3.7x |
Cash flow
Projections
Project Tactile Systems Technology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Tactile Systems Technology reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 6 of 9 | 8 of 9 |
| Rule of 40 | 23.4% | 19.8% | 24.7% |
| Altman Z'' | 5.40 | 6.70 | 8.52 |
| Accruals ratio | −2.7% | −8.2% | −8.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 6 of 9 | 6 of 9 | 8 of 9 |
Compare
Put Tactile Systems Technology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Tactile Systems Technology | FY25 | 12.5% | 8.9% | 12.3% | 12.6% | −2.3x | 8 | |
| Angiodynamics | FY26 | 9.5% | −12.5% | 0.2% | −24.6% | — | 4 | Compare |
| PROCEPT BioRobotics | FY25 | 37.2% | −33.7% | −18.9% | −65.4% | — | 5 | Compare |
| LeMaitre Vascular | FY25 | 13.5% | 27.2% | 29.8% | 25.5% | −2.4x | 5 | Compare |
| Artivion | FY25 | 13.6% | 7.7% | 0.2% | 3.9% | 2.7x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 84 | 109 | 144 | 190 | 187 | 208 | 247 | 274 | 293 | 330 |
| Revenue growth | 34.5% | 29.3% | 31.5% | 31.8% | −1.2% | 11.2% | 18.6% | 11.2% | 6.8% | 12.5% |
| Gross profit | 62 | 80 | 102 | 134 | 133 | 148 | 176 | 195 | 217 | 250 |
| Research and development | 4 | 5 | 5 | 5 | 5 | 6 | 7 | 8 | 9 | 8 |
| Operating income | 4 | 4 | 3 | 10 | −4 | −2 | −13 | 18 | 22 | 29 |
| Net income | 3 | 6 | 7 | 11 | −1 | −12 | −18 | 28 | 17 | 19 |
| Diluted EPS (US$) | 0.15 | 0.31 | 0.34 | 0.56 | −0.03 | −0.60 | −0.89 | 1.23 | 0.70 | 0.82 |
| Diluted shares (millions) | 11 | 19 | 19 | 20 | 19 | 20 | 20 | 23 | 24 | 23 |
| Cash flow | ||||||||||
| Cash from operations | 7 | 4 | 9 | 2 | 3 | 3 | 5 | 36 | 41 | 43 |
| Capital expenditure | 1 | 4 | 4 | 5 | 2 | 2 | 2 | 2 | 2 | 2 |
| Free cash flow | 6 | 0 | 5 | −3 | 1 | 1 | 3 | 34 | 38 | 40 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 27 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 8 | 10 | 11 | 10 | 10 | 8 | 8 | 8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 42 | 44 | 46 | 45 | 48 | 28 | 22 | 61 | 94 | 83 |
| Debt incl. finance leases | — | — | — | — | — | 30 | 24 | 29 | 26 | 0 |
| Total assets | 74 | 88 | 107 | 152 | 174 | 244 | 255 | 281 | 298 | 274 |
| Total liabilities | 14 | 16 | 18 | 39 | 49 | 116 | 134 | 88 | 81 | 55 |
| Shareholders' equity | 60 | 73 | 89 | 113 | 125 | 128 | 121 | 194 | 217 | 219 |
| Margins and ratios | ||||||||||
| Gross margin | 72.9% | 73.5% | 71.1% | 70.8% | 71.0% | 71.2% | 71.3% | 71.1% | 74.0% | 75.9% |
| Operating margin | 5.0% | 3.6% | 2.1% | 5.5% | −1.9% | −0.8% | −5.2% | 6.6% | 7.6% | 8.9% |
| Net margin | 3.4% | 5.4% | 4.6% | 5.8% | −0.3% | −5.7% | −7.2% | 10.4% | 5.8% | 5.8% |
| Free cash flow margin | 7.4% | 0.4% | 3.4% | −1.6% | 0.4% | 0.2% | 1.4% | 12.2% | 13.1% | 12.3% |
| Rule of 40 (growth + FCF margin) | 41.9% | 29.7% | 34.9% | 30.3% | −0.8% | 11.4% | 20.0% | 23.4% | 19.8% | 24.7% |
| Return on capital | — | — | — | — | — | — | −8.0% | 12.7% | 10.3% | 12.6% |
| Return on equity | 10.7% | 8.8% | 8.2% | 10.9% | −0.5% | −9.3% | −14.3% | 18.1% | 8.3% | 8.8% |
| Return on assets | 5.2% | 7.2% | 6.8% | 8.5% | −0.4% | −5.7% | −7.2% | 10.6% | 5.8% | 6.7% |
| Net debt to EBITDA | — | — | — | — | — | 0.9x | — | −1.3x | −2.4x | −2.3x |